Australian Particle Therapy Clinical Quality Registry


Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. Comparing the long-term toxicities of photon and proton radiation therapy.

For more about ASPIRE visit: https://www.protontherapy.sahmri.org.au/about-aptcqr/

Primary Sponsor

South Australian Health & Medical Research Institute (Australian Bragg Centre for Proton Therapy and Research)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Trial Chairperson

A/Prof Hien Le, Royal Adelaide Hospital, SA

Trial Contact

ASPIRE@sahmri.com

Clinical Trial Registration

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Related Post

Dr Anna Lawless, EI SIG Chair 2025
10 December, 2025

Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers

SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr

9 December, 2025

TROG’s inaugural Km’s for Cancer Research brings community together to support our work

LATEST NEWS: 9 December 2025 As we wrap up